Syra Health Corp. released its financial results for the third quarter ended September 30, 2026, on November 3, 2026, reporting record quarterly revenue and a third consecutive profitable quarter.

Key Highlights

  • Record quarterly revenue: Net revenues reached $2,557,295 in Q3 2026, up 52% from $1,687,971 in Q3 2025, according to the filing.
  • Net income of $344,610: The company reported net income of $344,610 in Q3 2026, compared with a net loss of $(225,902) in Q3 2025, a year-over-year improvement of $570,512.
  • Record gross margin: Gross profit margin widened by 1,340 basis points to 46.3% in Q3 2026, up from 32.9% in the prior-year period, surpassing the prior Company record of 44.5%.
  • Positive EBITDA: EBITDA turned positive at $301,725 in Q3 2026, a $520,326 improvement from a loss of $(218,601) in Q3 2025.
  • Nine-month net income: For the nine months ended September 30, 2026, the company generated net income of $835,831 compared with a net loss of $(761,763) in the prior-year period.
  • Cash position: Cash and cash equivalents grew to $2,383,413 as of September 30, 2026, from $1,614,733 as of December 31, 2025, with no long-term debt reported.
  • Operating cash flow: Net cash provided by operating activities reached $975,023 for the nine months ended September 30, 2026, compared with net cash used of $(158,554) in the prior-year period.

Syra Health Q3 2026 Revenue Mix, Margins, and Cost Trends

According to the filing, Syra Health Corp. (OTCQB:SYRA) reported Q3 2026 net revenues of $2,557,295, a 52% increase from $1,687,971 in Q3 2025. The company disclosed that its population health solutions segment grew 52% year-over-year to $1,943,788, while healthcare workforce revenue increased 50% to $613,507 from $407,960 in the prior-year period. The filing attributed the gross margin expansion to "a favorable revenue mix and ongoing operating leverage."

On the cost side, the company disclosed that salaries and benefits grew to $440,172 in Q3 2026 from $336,390 in Q3 2025, reflecting added headcount. Professional services declined 9% to $175,295 from $191,726, and selling, general and administrative expenses fell 12% to $222,141 from $252,384. Research and development expenses increased to $46,716 from $816 in Q3 2025, which the filing attributed to build-out of Syrenity Enterprise, described as the company's B2B mental and behavioral health solution. Depreciation dropped 87% to $715 from $5,396.

The balance sheet as of September 30, 2026, showed total assets of $4,225,390, total liabilities of $1,201,696, and total stockholders' equity of $3,023,694. The accumulated deficit stood at $(8,884,695). The filing also noted that following CMS approval of Syrenity for the ACCESS Model, the company is actively recruiting Accountable Care Organizations to utilize the platform in partnership with HealthSync. Regarding the outlook, the filing stated the company "remains on track to achieve its previously stated goal of full-year profitability in 2026," while cautioning that "the timing of awards, revenue recognition, and contract milestones" may cause quarter-to-quarter variability. These statements are the company's own and subject to its cautionary language.

What Was Disclosed

Syra Health disclosed Q3 2026 and nine-month financial results showing record quarterly revenue of $2,557,295, a third consecutive profitable quarter with net income of $344,610, gross margin of 46.3%, positive EBITDA of $301,725, and cash of $2,383,413 with no long-term debt.